EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

HER-3 is becoming an attractive target for antibody–drug conjugate (ADC)-based therapy. Indeed, this receptor and its ligands are found to be overexpressed in several malignancies, and re-activation of its downstream signaling axis is known to play a critical role in modulating the sensitivity of ta...

Full description

Bibliographic Details
Main Authors: Emily Capone, Rossano Lattanzio, Fabio Gasparri, Paolo Orsini, Cosmo Rossi, Valentina Iacobelli, Vincenzo De Laurenzi, Pier Giorgio Natali, Barbara Valsasina, Stefano Iacobelli, Gianluca Sala
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Pharmaceutics
Subjects:
antibody–drug conjugates
HER-3
targeted therapy
duocarmycin
Online Access:https://www.mdpi.com/1999-4923/13/4/483

Internet

https://www.mdpi.com/1999-4923/13/4/483

Similar Items